Natera, Inc. (NTRA) Announced Q1 2026 Earnings on May 7, 2026, Reporting "revenues of $697 million in Q1"

Natera reported first quarter 2026 financial results with "revenues of $697 million in Q1," which represented "39% growth over last year". The company achieved "gross margins coming in at just under 65%" for the quarter.

Management noted that the "rapid increase in volumes in Q1 actually harmed margins by roughly 2 percentage points because we had more samples in process in the lab at the close of the quarter than normal".Management highlighted a milestone of "delivering 1 million units in a single quarter". The oncology division "processed 249,000 clinical oncology units in the quarter," representing a record increase.

The company also saw a successful launch of its "fetal focused product," which is "approaching a run rate of nearly 200,000 focus orders". Additionally, the company is seeing success from its "integration with Onco EMR" and the acquisition of Foresight Diagnostics, leveraging "phased variant technology" to drive biopharma interest.

For forward guidance, Natera announced it will "fully reset the revenue guide range by more than $120 million and increase our gross margin guidance to 65% at the midpoint". Management also plans to "bump R&D expectations by $50 million, primarily to pull forward" clinical trials.

Notable updates included positive interim data from the ALPHA3 trial sponsored by Allogene Therapeutics, the progression of the FIND CRC screening study, and preparations for a broad commercial launch of Signatera in Japan with PMDA approval remaining "on track for Q2 2026".TWEETNatera $NTRA reported Q1 2026 earnings: 📊 Revenue: $697 million (Q), 39% growth ✅ Momentum: "integration with Onco EMR" & "record growth quarter for oncology" 🐂 Bull: "gross margins coming in at just under 65%" 🐻 Bear: "we had more samples in process in the lab" 🎧 Listen: [LINK]